sechenovSechenov Medical JournalСеченовский вестник2218-73322658-3348Сеченовский Университетsechenov-564Research ArticleCARDIOLOGYКАРДИОЛОГИЯTHIAZIDE DIURETICS IN TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSIONТИАЗИДНЫЕ ДИУРЕТИКИ В ЛЕЧЕНИИ БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙЧазовЕ. И.ChazovE. I.

академик РАН и РАМН, генеральный директор

РатоваЛ. Г.RatovaL. G.

к.м.н., ведущий научный сотрудник отдела системных гипертензий, ответственный секретарь Российского медицинского общества по артериальной гипертонии

ФГУ «РКНПК Мииздравсоиразвития России»Russian Federation20103006201002813Copyright © Chazov E.I., Ratova L.G., 20102010Чазов Е.И., Ратова Л.Г.Chazov E.I., Ratova L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sechenovmedj.com/jour/article/view/564

Role of thiazide diuretics in treatment of arterial hypertension and their influence on long-term prognosis of patients according to the results of placebo-controlled clinical studies are described

Представлены роль тиазидных диуретиков в лечении артериальной гипертензии и их влияние на долгосрочный прогноз пациентов исходя из результатов контролируемых клинических исследований

артериальная гипертензиятиазидные диуретикилечениепрогнозarterial hypertensionthiazide diureticstreatmentprognosisReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации // Кардиоваскуляр. тер. и профилактика. Прил. 2. — 2008. — Т. 7, № 6.Диагностика и лечение артериальной гипертензии. Российские рекомендации // Кардиоваскуляр. тер. и профилактика. Прил. 2. — 2008. — Т. 7, № 6.Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III // Системные гипертензии. — 2010. — № 1. — С. 8—15.Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III // Системные гипертензии. — 2010. — № 1. — С. 8—15.Тареев Е.М. Гипертоническая болезнь. — М.: Медгиз, 1948.Тареев Е.М. Гипертоническая болезнь. — М.: Медгиз, 1948.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg / / JAMA. — 1967. - Vol. 202, N 11. - P. 1028-1034.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg / / JAMA. — 1967. - Vol. 202, N 11. - P. 1028-1034.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg // JAMA. - 1970. - Vol. 213, N 7. - P. 1143-1152.Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg // JAMA. - 1970. - Vol. 213, N 7. - P. 1143-1152.Blood Pressure Lowering Treatment Trialists’ Collaboration; Turnbull F., Neal B., Algert C. et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus; results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165. — P. 1410—1419.Blood Pressure Lowering Treatment Trialists’ Collaboration; Turnbull F., Neal B., Algert C. et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus; results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165. — P. 1410—1419.Dahlof B., Sever P.S., Poulter N.R.,for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial / / Lancet. — 2005. — Vol. 366. - P. 895-906.Dahlof B., Sever P.S., Poulter N.R.,for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial / / Lancet. — 2005. — Vol. 366. - P. 895-906.DahlufB., DevereuxR.B., Kjeldsen S.E. etal. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. - P. 995-1003.DahlufB., DevereuxR.B., Kjeldsen S.E. etal. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. - P. 995-1003.Fletcher A., Amery A., Birkenlrager W. et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly / / J. Hypertens. — 1991. — Vol. 9, N 3. - P 225-230.Fletcher A., Amery A., Birkenlrager W. et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly / / J. Hypertens. — 1991. — Vol. 9, N 3. - P 225-230.Gress T.W., Nieto F.J., Shahar E. et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes // N. Engl. J. Med. - 2000. - Vol. 342. - P 905-912.Gress T.W., Nieto F.J., Shahar E. et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes // N. Engl. J. Med. - 2000. - Vol. 342. - P 905-912.Hansson L., Dahlof B., Ekbom T. et al. Key learnings from the STOP-Hypertension study: an update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly / / Cardiovasc. Drugs Ther. — 1991. — Suppl. 6. - P 1253-1255.Hansson L., Dahlof B., Ekbom T. et al. Key learnings from the STOP-Hypertension study: an update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly / / Cardiovasc. Drugs Ther. — 1991. — Suppl. 6. - P 1253-1255.Hansson L., Dahlof B., Ekbom T. et al. Prognostic factors in the treatment of mild hypertension. The Management Committee of the Australian National Blood Pressure Study // Circulation. — 1984. — Vol. 69. — P. 668—676.Hansson L., Dahlof B., Ekbom T. et al. Prognostic factors in the treatment of mild hypertension. The Management Committee of the Australian National Blood Pressure Study // Circulation. — 1984. — Vol. 69. — P. 668—676.Hansson L., Hedner 77, Lund-Johansen P. etal. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356. — P. 359-365.Hansson L., Hedner 77, Lund-Johansen P. etal. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356. — P. 359-365.Hansson L., Lindholm L.H., Ekbom T. et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. - 1999. - Vol. 354. - P. 1751-1756.Hansson L., Lindholm L.H., Ekbom T. et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. - 1999. - Vol. 354. - P. 1751-1756.Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. — 1999. - Vol. 353. - P. 611-616.Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. — 1999. - Vol. 353. - P. 611-616.Hypertension: Pathophysiology, Diagnosis, and Management / Eds J.H. Laragh, B.M. Brenner. — N.Y.: Raven Press, 1990.Hypertension: Pathophysiology, Diagnosis, and Management / Eds J.H. Laragh, B.M. Brenner. — N.Y.: Raven Press, 1990.Kaplan N.M. Clinical Hypertension. 10th ed. — Lippincott Williams and Wilkins, 2010.Kaplan N.M. Clinical Hypertension. 10th ed. — Lippincott Williams and Wilkins, 2010.Krum H., Skiba M., Gilbert R.E. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy / / Diabet. Med. — 2003. — Vol. 20, N 9. — P. 708-712.Krum H., Skiba M., Gilbert R.E. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy / / Diabet. Med. — 2003. — Vol. 20, N 9. — P. 708-712.LaCroix A.Z., Ott S.M., Ichikawa L. et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo- controlled trial / / Ann. Intern. Med. — 2000. — Vol. 133. - P. 516-526.LaCroix A.Z., Ott S.M., Ichikawa L. et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo- controlled trial / / Ann. Intern. Med. — 2000. — Vol. 133. - P. 516-526.Me Mahon F.G. Management of Essential Hypertension. — Mt. Kisko: Futura Publishing, 1978.Me Mahon F.G. Management of Essential Hypertension. — Mt. Kisko: Futura Publishing, 1978.Medical research council working party. Medical research council trial to treatment of hypertension in older adults: principal results / / BMJ. — 1992. — Vol. 304. — P. 405-412.Medical research council working party. Medical research council trial to treatment of hypertension in older adults: principal results / / BMJ. — 1992. — Vol. 304. — P. 405-412.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) //JAMA. - 2002. - Vol. 288. - P. 2981-2997.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) //JAMA. - 2002. - Vol. 288. - P. 2981-2997.Moser M. Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument for//J. Clin. Hypertens (Greenwich). — 2005. - Vol. 7, N 2. - P. 111-116.Moser M. Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument for//J. Clin. Hypertens (Greenwich). — 2005. - Vol. 7, N 2. - P. 111-116.Neaton J.D., Grimm R.H.Jr, Prineas R.J. el ai Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group / / JAMA. — 1993. - Vol. 270. - P. 713-724.Neaton J.D., Grimm R.H.Jr, Prineas R.J. el ai Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group / / JAMA. — 1993. - Vol. 270. - P. 713-724.Papademetriou V, Burris J.F., Notargiacomo A. et al. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension//Arch. Intern. Med. — 1988. — Vol. 148. - P. 1272-1276.Papademetriou V, Burris J.F., Notargiacomo A. et al. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension//Arch. Intern. Med. — 1988. — Vol. 148. - P. 1272-1276.Psaty B., Lumley 71, FurbergC. Health outcomes associated with various antihypertensive therapies used as first-line 31. agents//JAMA. - 2003. - Vol. 289. - P. 2534-2544.Psaty B., Lumley 71, FurbergC. Health outcomes associated with various antihypertensive therapies used as first-line 31. agents//JAMA. - 2003. - Vol. 289. - P. 2534-2544.Psaty B.M., Smith N.S., Siscovick D.S. et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis / / JAMA. - 1997. - Vol. 277. - P. 739-745.Psaty B.M., Smith N.S., Siscovick D.S. et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis / / JAMA. - 1997. - Vol. 277. - P. 739-745.Reid I.R., Ames R.W., Orr-Walker B.J. et al. Hydrochlorothiazide Reduces loss of Cortical Bone in Normal Postmenopausal Women: A Randomized Controlled Trial / / Am. J. Med. — 2000. — Vol. 109. — P. 362-370.Reid I.R., Ames R.W., Orr-Walker B.J. et al. Hydrochlorothiazide Reduces loss of Cortical Bone in Normal Postmenopausal Women: A Randomized Controlled Trial / / Am. J. Med. — 2000. — Vol. 109. — P. 362-370.Schoofs M.W., van der Klift M., Hofman A. et al. Thiazide diuretics and the risk for hip fracture//Ann. Intern. Med.— 2003. - Vol. 139. - P. 476-482.Schoofs M.W., van der Klift M., Hofman A. et al. Thiazide diuretics and the risk for hip fracture//Ann. Intern. Med.— 2003. - Vol. 139. - P. 476-482.Spence J.D., Huff M., Barnett P.A. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison // Can. J. Clin. Pharmacol. — 2000. — Vol. 7, N 1. — P. 32-37. Wasnich R., Davis J., He Y. et al. A randomized, doublemasked, placebo-controlled trial of chlorthalidone and bone loss in elderly women / / Osteoporos. Int. — 1995. — Vol. 5, N 4. - P. 247-251.Spence J.D., Huff M., Barnett P.A. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison // Can. J. Clin. Pharmacol. — 2000. — Vol. 7, N 1. — P. 32-37. Wasnich R., Davis J., He Y. et al. A randomized, doublemasked, placebo-controlled trial of chlorthalidone and bone loss in elderly women / / Osteoporos. Int. — 1995. — Vol. 5, N 4. - P. 247-251.

The authors declare that there are no conflicts of interest present.